Skip to main content
European Commission logo
English English
CORDIS - EU research results

3D Living Tissues

Project description

A bioprinted 3D lymph node model for drug discovery

More than 90 % of oncology drugs fail in clinical trials. This is attributed to the unreliable in vitro models used for drug discovery. The scope of the EU-funded 3DLT project is to bring to market a proprietary 3D bioprinting technology that uses live human cells to generate tissues that closely resemble their human counterparts. Researchers have developed a 3D lymph node as a platform for testing new immunotherapies against cancer. The project's work includes assessing the economic feasibility of bringing the product to market, and making the necessary industrial and commercial partnerships to reach this objective.


Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
43122 PARMA

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Nord-Est Emilia-Romagna Parma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00